June 2012

In our June Research Report, OneMedResearch explores the potential impact of the JOBS Act on the life sciences sector. This month we have also initiated coverage on Opexa Therapeutics and OncoSec Medical, two companies with disruptive technology and the potential for significant returns. In addition, in this issue we provide monthly company updates.

We hope you will find this research report very valuable and we appreciate your feedback, insights and questions. You can reply to this email to get in touch with us.

Below is a list of companies covered in this issue.

OncoSec Medical. This San Diego-based company has a treatment for Metastatic Melanoma that appears to have some excellent results. See an explanation of electroporation and the intriguing market opportunity in our Initiation Report on OncoSec on page 7-8 .

Opexa Therapeutics. This Houston-based company is in phase IIb with an autologous T-cell therapy to treat Secondary Progress Multiple Sclerosis (SPMS). See our Initiation Report on Opexa on page 5-6 of the June Research Report.

Additional companies in this report:

Advaxis. Immunotherapy vaccine technology in clinical development to treat CIN/cervical cancer and other cancers.

Biovest. Cancer vaccine to treat non-Hodgkins Lymphoma automated cell culture instrumentation systems.

NanoViricides. Nanoscale processes to develop anti-virals. Indications include flu, HIV and external eye viruses.

Wound Management. Lead product CellerateRX delivers essential collagen to a wound immediately.

Tianyin Pharmaceuticals. Patented biopharmaceutical, modernized traditional Chinese medicine, Branded generics.

PLC. Lead product RenalGuard for contrast-induced nephropathy (CIN) during iodinated contrast procedures.

Novadaq. Real-time fluorescence imaging to assess organs, tissues, and vessels during surgery.

To view the full report, click here.

The comments are closed.